Dominant monoallelic variant in the PAK2 gene causes Knobloch syndrome type 2.


Journal

Human molecular genetics
ISSN: 1460-2083
Titre abrégé: Hum Mol Genet
Pays: England
ID NLM: 9208958

Informations de publication

Date de publication:
17 12 2021
Historique:
received: 06 10 2020
revised: 11 01 2021
accepted: 31 01 2021
pubmed: 12 3 2021
medline: 8 4 2022
entrez: 11 3 2021
Statut: ppublish

Résumé

Knobloch syndrome is an autosomal recessive phenotype mainly characterized by retinal detachment and encephalocele caused by biallelic pathogenic variants in the COL18A1 gene. However, there are patients clinically diagnosed as Knobloch syndrome with unknown molecular etiology not linked to COL18A1. We studied an historical pedigree (published in 1998) designated as KNO2 (Knobloch type 2 syndrome with intellectual disability, autistic behavior, retinal degeneration, encephalocele). Whole exome sequencing of the two affected siblings and the normal parents resulted in the identification of a PAK2 non-synonymous substitution p.(Glu435Lys) as a causative variant. The variant was monoallelic and apparently de novo in both siblings indicating a likely germ-line mosaicism in one of the parents; the mosaicism, however, could not be observed after deep sequencing of blood parental DNA. PAK2 encodes a member of a small group of serine/threonine kinases; these P21-activating kinases (PAKs) are essential in signal transduction and cellular regulation (cytoskeletal dynamics, cell motility, death and survival signaling and cell cycle progression). Structural analysis of the PAK2 p.(Glu435Lys) variant that is located in the kinase domain of the protein predicts a possible compromise in the kinase activity. Functional analysis of the p.(Glu435Lys) PAK2 variant in transfected HEK293T cells results in a partial loss of the kinase activity. PAK2 has been previously suggested as an autism-related gene. Our results show that PAK2-induced phenotypic spectrum is broad and not fully understood. We conclude that the KNO2 syndrome in the studied family is dominant and caused by a deleterious variant in the PAK2 gene.

Identifiants

pubmed: 33693784
pii: 6159698
doi: 10.1093/hmg/ddab026
doi:

Substances chimiques

PAK2 protein, human EC 2.7.11.1
p21-Activated Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-9

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Auteurs

Stylianos E Antonarakis (SE)

Department of Genetic Medicine and Development, University of Geneva Medical Faculty, Geneva 1211, Switzerland.
iGE3 Institute of Genetics and Genomics of Geneva, Geneva 1211, Switzerland.

Aleš Holoubek (A)

Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague 12820, Czech Republic.

Melivoia Rapti (M)

Department of Endocrinology Diabetes and Metabolism, Lausanne University Hospital, Lausanne 1011, Switzerland.

Jesse Rademaker (J)

Department of Endocrinology Diabetes and Metabolism, Lausanne University Hospital, Lausanne 1011, Switzerland.

Jenny Meylan (J)

Department of Endocrinology Diabetes and Metabolism, Lausanne University Hospital, Lausanne 1011, Switzerland.

Justyna Iwaszkiewicz (J)

Molecular Modeling Group, Swiss Institute of Bioinformatics, Lausanne 1015, Switzerland.

Vincent Zoete (V)

Molecular Modeling Group, Swiss Institute of Bioinformatics, Lausanne 1015, Switzerland.
Department of Fundamental Oncology, Ludwig Institute for Cancer Research, Lausanne University, Epalinges 1066, Switzerland.

Callum Wilson (C)

National Metabolic Service, Starship Children's Hospital, Auckland 1142, New Zealand.

Juliet Taylor (J)

Genetic Health Services New Zealand - Northern Hub, Auckland City Hospital, Auckland 1142, New Zealand.

Muhammad Ansar (M)

Institute of Molecular and Clinical Ophtalmology Basel (IOB), Basel 4031, Switzerland.

Christelle Borel (C)

Department of Genetic Medicine and Development, University of Geneva Medical Faculty, Geneva 1211, Switzerland.

Olivier Menzel (O)

Health 2030 Genome Center, Foundation Campus Biotech Geneva Foundation, Geneva 1202, Switzerland.

Kateřina Kuželová (K)

Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague 12820, Czech Republic.

Federico A Santoni (FA)

Department of Endocrinology Diabetes and Metabolism, Lausanne University Hospital, Lausanne 1011, Switzerland.
Faculty of Biology and Medicine, University of Lausanne, Lausanne 1011, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH